PEDIG | ATS18 – Pediatric Amblyopia Study

 

Why we are doing this study:
This is a study for children age 5 years to 16 years old who have amblyopia, sometimes referred to as lazy eye, a condition where one of the eyes does not work as well as the other. This study will look at using a game played on an iPad® or putting a patch over the good eye to treat amblyopia. We are trying to find out if playing this game works compared to patching.

Who can be in the study:
Children aged 5 years to 16 years with amblyopia. (Currently recruiting ages 13-16 years.)

No amblyopia treatment (atropine, patching, Bangerter, vision therapy) in the past 2 weeks.

Specific screening questions will be asked before scheduling a study appointment.

What the study involves:
The length of the study is 16 weeks with check-ups at 4, 8, 12, and 16 weeks after the initial visit. Each visit will take approximately 1 hour. At the end of your first study visit, your child will be randomized (like the toss of a coin) to either computer game or patching. Your child will either be asked to play a computer game on an iPad for 1 hour a day, 7 days a week for 16 weeks OR your child will be asked to wear a patch 2 hours per day, 7 days per week for 16 weeks. At each visit, your child will:

  • Have his/her vision checked.
  • Have stereoacuity (depth perception) checked.
  • Have his/her eye alignment checked.
  • Complete other procedures designed to see if your child’s qualifies for the study.
  • Parents will complete a questionnaire at each visit.

Will you directly benefit from the study?
There may or may not be a benefit to your child by being in the study, but there is no guarantee.

Other things you should know about the study:

  • Parental permission is required for minors (under age 18) to participate in this study, so a parent will need to be present during the enrollment visit.
  • The study will loan an iPad to your child.
  • You will receive $50 for each completed visit for your time for the study.

Principle Investigator: Marilyn Vricella
For more information, contact the Clinical Vision Research Center.